Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature

Publikation: Bidrag til tidsskriftReviewForskningpeer review


  1. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVIDEHA

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Chimerism analysis following hematopoietic stem cell transplantation (HSCT) for leukemia is routinely applied in parallel with quantification of minimal residual disease (MRD) to identify imminent relapse. In the past decades, new methods with a lower limit of detection compared to standard methods have been developed, so-called microchimerism analysis. Microchimerism analysis is fast, simple, applicable across pre-HSCT disease-type and can be applied on peripheral blood allowing frequent testing during follow-up. Monitoring of microchimerism in blood could replace repeated bone marrow analysis for MRD and allow earlier detection of imminent relapse or graft failure. Clinical studies in single center cohorts have shown conflicting but promising results. There is currently no consensus on the interpretation of microchimerism analysis and heterogeneity of studies remains a major obstacle for inter-study comparisons and meta-analysis in this field. We have conducted a systematic review of studies investigating associations between microchimerism and relapse of leukemia post-HSCT. We summarize current evidence and provide suggestions for future research.

Sider (fra-til)100673
StatusUdgivet - nov. 2020

Bibliografisk note

Copyright © 2020 Elsevier Ltd. All rights reserved.

ID: 61695986